AbbVie Completes $10.9 Billion Acquisition of Apogee Therapeutics
AbbVie has finalized its acquisition of Apogee Therapeutics for approximately $10.9 billion, marking the company's largest bolt-on deal since 2019. The transaction was first reported in June by The Financial Times and is now complete following regulatory approvals and shareholder consent. The acquisition expands AbbVie’s portfolio with Apogee’s late-stage pipeline of therapies for chronic kidney disease (CKD) and other conditions, including a lead candidate currently under FDA review. This move aligns with AbbVie's strategy to strengthen its presence in key therapeutic areas through strategic acquisitions.
